[HTML][HTML] Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging
and AD are associated with apparent metabolic alterations. As developing effective …
and AD are associated with apparent metabolic alterations. As developing effective …
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
SN AUSTAD, S BALLINGER… - Acta Pharmaceutica …, 2022 - pesquisa.bvsalud.org
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging
and AD are associated with apparent metabolic alterations. As developing effective …
and AD are associated with apparent metabolic alterations. As developing effective …
[HTML][HTML] Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
SN Austad, S Ballinger, TW Buford… - Acta Pharmaceutica …, 2022 - ncbi.nlm.nih.gov
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging
and AD are associated with apparent metabolic alterations. As developing effective …
and AD are associated with apparent metabolic alterations. As developing effective …
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
SN Austad, S Ballinger, TW Buford… - Acta …, 2022 - pubmed.ncbi.nlm.nih.gov
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging
and AD are associated with apparent metabolic alterations. As developing effective …
and AD are associated with apparent metabolic alterations. As developing effective …
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.
SN Austad, S Ballinger, TW Buford… - Acta Pharmaceutica …, 2021 - europepmc.org
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging
and AD are associated with apparent metabolic alterations. As developing effective …
and AD are associated with apparent metabolic alterations. As developing effective …
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
SN AUSTAD, S BALLINGER… - Acta Pharmaceutica …, 2022 - pesquisa.bvsalud.org
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging
and AD are associated with apparent metabolic alterations. As developing effective …
and AD are associated with apparent metabolic alterations. As developing effective …